EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/4b222506acd0a6238150f06a032c363f.pdf

Abstract Title

First Name *

Hiddo

Last Name *

J.L. Heerspink

Co-author 1

David C. Wheeler d.wheeler@ucl.ac.uk University College London Department of Renal Medicine London

Co-author 2

Ricardo Correa-Rotter correarotter@gmail.com The National Medical Science and Nutrition Institute Salvador Zubiran Department of Nephrology and Mineral Metabolism Mexico city

Co-author 3

Jamie P. Dwyer jamie.dwyer@hsc.utah.edu University of Utah Division of Nephrology and Hypertension Salt Lake City

Co-author 4

Anna Maria Langkilde AnnaMaria.Langkilde@astrazeneca.com AstraZeneca BioPharmaceuticals R&D Gothenburg

Co-author 5

Patrick B. Mark Patrick.Mark@glasgow.ac.uk University of Glasgow / Queen Elizabeth University Hospital School of Cardiovascular and Metabolic Health / Renal & Transplant Unit Glasgow

Co-author 6

Michal Nowicki michal.nowicki@umed.lodz.pl Medical University of Lodz Department of Nephrology, Hypertension and Kidney Transplantation Lodz

Co-author 7

Peter Rossing peter.rossing@regionh.dk University of Copenhagen / Steno Diabetes Center Copenhagen Department of Clinical Medicine Gentofte / Copenhagen

Co-author 8

Robert D. Toto Robert.Toto@UTSouthwestern.edu UT Southwestern Medical Center Department of Internal Medicine Dallas

Co-author 9

Glenn M. Chertow gchertow@stanford.edu Stanford University Departments of Medicine and Epidemiology and Population Stanford

Co-author 10

Niels Jongs n.jongs@umcg.nl University of Groningen Department of Clinical Pharmacy and Pharmacology Groningen

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15